Hydroxychloroquine did not have any effect on viral clearance in a RCT. High proportion with adverse events in HCQ arm but most mild. https://t.co/fn66SgBqg3
It’s great to see that our paper on reverse genetics system for SARS-Cov-2 and other positive strand RNA viruses has been selected as Editor’s Highlights in “Microbiology and infectious diseases” web page of Nature Communications https://t.co/j0Z1VPyg9y.
Amazing case report. The medicine of tomorrow. 5 week old boy admitted to NICU. Within 37 hours he had his whole genome sequenced, gene defect identified, treatment ordered and received by patient. Within 6 hr symptoms resolved. https://t.co/UYSJSURQHW
@yxsetoh Great historical summary, Setoh - thanks. Just leaves me to add that the experiments for the original WNV CPER development and for the latest SARS-CoV-2 CPER (in PC3) I actualy did myself with some help from the team, incl. you. Doing experiments still feels me with joy!
@JodyPeters20 @Alberto91592929 @yxsetoh Couldn’ agree more, Jody and sorry for mistyping James' last name - it should be James Potter of course. Our paper establishes CPER for for different polyA tail-containing RNA viruses, SARS-CoV-2 (~30kb), Casuarina virus (~20kb), Ross River virus (~12kb) and Norovirus (~7.5kb).
@DWatterson_@NatureComms@AndreasSuhrbier@JodyPeters20@JasonMack1234 @Alberto91592929 Indeed, Alberto was instrumental for this work with long hours in PC3 - huge thanks to him and also to all other joint first authors - Julian De Jun Sng, Rhys Parry, Josh Deerain, James Hardy and Yin Xiang Setoh. They all made vital contributions. Also thanks to QIMRB team.
Our paper on CPER-based reverse genetics system for SARS-COV-2 and other positive strand RNA is finally out in Nature Communications https://t.co/bkuKx5pwL6 big thanks to our collaborators at UQ, Uni Melb, Monash, and Queensland Health.
Our complete mapping of mutations to #SARSCoV2 RBD that reduce binding by convalescent human plasma is out in @cellhostmicrobe (https://t.co/F2sz3HL9tE). Right now E484K getting lot of attention, but I want to emphasize what our results suggest to keep eyes on in *future* (1/n)
More details now available for South African trial w/ Astra Zeneca vaccine, regarding B.1.351 variant. Table updated, data here:
https://t.co/NekZxSDiL7 by @gksteinhauser
This is now the third paper to find a very very good immune response after one shot of mRNA vaccine in people who had a previous SARS-CoV-2 infection. Time to discuss policy changes, @DrNancyM_CDC@CDCDirector! https://t.co/jIwBCDqNd2
The emergence of SARS-CoV-2 variants serve as a powerful reminder that viruses by their very nature mutate, and that science may need to adapt if they are to remain effective against them🔬
Statement from CEPI and our COVAX partners @gavi@WHO⏬
https://t.co/VkkEPbRlQL
Great interview with Russell Basser from @CSL walking through the update on our @UQ_News#COVID19#vaccine. While not the outcome we wanted, big shoutout to the Australian media for the accurate and balanced coverage, it means a lot to whole team who worked so hard this year! 🙏
It has been a real inspiration to see how much can be achieved with a great team of likeminded and highly motivated researchers. You guys gave it your best shot and I am sure you will rebounce back stronger than before.
Thank you to our absolutely incredible team of scientists for their work on the #UQ/@CSLBehring COVID-19 vaccine, as well as our generous supporters and donors. While the vaccine will not be progressing, we're extremely proud of their hard work. Read more: https://t.co/GASLW4Z7go
this makes sense, athough vaccinated people can do it themselves with other available antibody tests if they really want to know whether they are vaccinated with vaccine or with placebo
Roche is partnering with Moderna to include a COVID-19 antibody test in the mRNA specialist's ongoing vaccine trials, the Swiss drugmaker said on Wednesday, potentially demonstrating if the vaccine is working. https://t.co/nhwmxcPnJC
We established work with SARS-CoV-2 virus and developed a simple and rapid way to manipulate viral genome. With #nhmrc funding we could apply this to figure out how the virus causes disease and develop new antiviral drugs #advanceaustraliacare#auspol#SaveOzScience @GregHuntMP
We’ve had many years of successive @nhmrc funding for our research on medically important viruses which led to multiple reserch discoveries and development of vaccine candidates. Continuing @nhmrc funding is absolutely vital!
#advanceaustraliacare#auspol#SaveOzScience
1/ I am thrilled to share my first first author paper with #sciencetwitter! In our paper @cellhostmicrobe, we characterize mammalian RTP4 as a species-specific inhibitor of #flaviviruses. Some highlights: https://t.co/yPD8DdX2gD